Analyst Price Target is $12.25
▲ +90.51% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for MiMedx Group in the last 3 months. The average price target is $12.25, with a high forecast of $14.00 and a low forecast of $11.00. The average price target represents a 90.51% upside from the last price of $6.43.
Current Consensus is
Buy
The current consensus among 4 polled investment analysts is to buy stock in MiMedx Group. This Buy consensus rating has held steady for over two years.
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was incorporated in 2011 and is headquartered in Marietta, Georgia.
Read More
